{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046149","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.377748+00:00","generated_at":"2026-05-22T05:38:16.030703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Structure Therapeutics Q1 net loss $46.8M; cash $836.9M; aleniglipron Ph2b data expected by year-end","bullets":["Net loss of $46.8M in Q1 2025 vs $26.0M in Q1 2024; R&D expenses $42.9M (up from $20.7M).","Cash, equivalents and short-term investments $836.9M as of March 31, 2025; funding through at least 2027.","Phase 2b ACCESS and ACCESS II fully enrolled; topline 36-week data for aleniglipron expected by year-end 2025.","Initiation of Phase 1 study for oral amylin agonist ACCG-2671 planned by year-end 2025; new preclinical data at ADA June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046149","json":"https://secwatch.observer/filing/0001104659-25-046149.json","markdown":"https://secwatch.observer/filing/0001104659-25-046149.md","text":"https://secwatch.observer/filing/0001104659-25-046149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/0001104659-25-046149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925046149/tm2514150d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:38:16.030703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}